$462.99
0.82% yesterday
Nasdaq, Dec 24, 07:47 pm CET
ISIN
US92532F1003
Symbol
VRTX

Vertex Pharmaceuticals Stock price

$462.99
+38.99 9.20% 1M
+12.72 2.83% 6M
+60.29 14.97% YTD
+54.81 13.43% 1Y
+173.30 59.82% 3Y
+228.53 97.47% 5Y
+338.15 270.87% 10Y
+434.20 1,508.16% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+3.78 0.82%
ISIN
US92532F1003
Symbol
VRTX
Industry

New AI Insights on Vertex Pharmaceuticals Insights AI Insights on Vertex Pharmaceuticals

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
-
Cash
$6.3b
Shares outstanding
254.0m
Valuation (TTM | estimate)
P/E
32.5 | 24.8
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
72.8%
Return on Equity
-3.3%
ROCE
22.3%
ROIC
26.6%
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$11.7b | $12.2b
EBITDA
$4.7b | $5.5b
EBIT
$4.5b | $5.3b
Net Income
$3.7b | $4.7b
Free Cash Flow
$3.3b
Growth (TTM | estimate)
Revenue
10.3% | 11.0%
EBITDA
5.1% | 19.3%
EBIT
5.8% | 21.4%
Net Income
866.0% | 986.2%
Free Cash Flow
346.9%
Margin (TTM | estimate)
Gross
86.3%
EBITDA
40.4% | 44.9%
EBIT
38.7%
Net
31.4% | 38.8%
Free Cash Flow
28.5%
More
EPS
$14.3
FCF per Share
$13.1
Short interest
2.0%
Employees
6k
Rev per Employee
$1.8m
Show more

Create a Free Account to create an Vertex Pharmaceuticals alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Vertex Pharmaceuticals Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

25x Buy
64%
13x Hold
33%
1x Sell
3%

Analyst Opinions

39 Analysts have issued a Vertex Pharmaceuticals forecast:

Buy
64%
Hold
33%
Sell
3%

Financial data from Vertex Pharmaceuticals

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
11,723 11,723
10% 10%
100%
- Direct Costs 1,609 1,609
9% 9%
14%
10,115 10,115
11% 11%
86%
- Selling and Administrative Expenses 1,644 1,644
13% 13%
14%
- Research and Development Expense 3,935 3,935
14% 14%
34%
4,737 4,737
5% 5%
40%
- Depreciation and Amortization 201 201
9% 9%
2%
EBIT (Operating Income) EBIT 4,536 4,536
6% 6%
39%
Net Profit 3,675 3,675
866% 866%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Vertex Pharmaceuticals directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vertex Pharmaceuticals Stock News

Neutral
Business Wire
3 days ago
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Inves...
Positive
Seeking Alpha
7 days ago
December's mixed performance for tech may be an early signal that leadership is narrowing, especially among the value-stretched stocks. Investors looking forward to 2026 may find better risk-adjusted opportunities in defensive sectors with select growth drivers. Rather than relying solely on traditional names, this article digs deeper into Quant Strong Buys that combine durable cash flows, esse...
Neutral
Seeking Alpha
9 days ago
Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal announcement. Vertex Pharmaceuticals lost value following disappointing clinical trial results in one of its pain therapy programs. We initiated a position in Advanced Micro Devices (AMD), a leading provider of high-performance computing and AI solutions.
More Vertex Pharmaceuticals News

Company Profile

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Head office United States
CEO Reshma Kewalramani
Employees 6,100
Founded 1989
Website www.vrtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today